F2 and End Stage Liver Disease: We also found no significant correlation between ELAVL1/CEACAM1 and the recipient/surgical parameters, including age, sex, race, model for end-stage liver disease (MELD) score, pretransplant blood and liver enzyme tests, bilirubin, prothrombin, and cold ischemia time (Supplemental Table 1B).